Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum

Abeona Therapeutics Inc ((ABEO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Abeona Therapeutics’ latest earnings call struck a cautiously upbeat tone as management highlighted strong early traction for its new gene therapy ZEVASKYN alongside disciplined pipeline investment. Executives acknowledged rising expenses, a wider net loss and cash burn, but argued that accelerating revenue, robust payer coverage and clean manufacturing performance position the company well despite launch and reimbursement complexities.

Early Commercial Revenue Traction

Abeona reported net product revenue of $8.7 million in Q1 2026, all from ZEVASKYN and driven by three commercially insured patients treated in the period. That marks a sharp acceleration from $2.4 million in Q4 2025, roughly a 262% quarter‑over‑quarter increase that signals meaningful early demand in a highly specialized market.

Patient Volume and QTC Network Expansion

Since launch, five patients have been treated with ZEVASKYN, including one in Q4 2025, three in Q1 2026 and one already treated in the current quarter. The company now counts six Qualified Treatment Centers across the U.S., targets seven by year‑end with potential to reach about 9–10, and sees a steady‑state cadence of roughly one patient per center each month.

Broad Payer Coverage and Market Access

Management emphasized that formal ZEVASKYN policies now cover 95% of commercially insured lives, a key de‑risking milestone for investors watching reimbursement. Importantly, Abeona reported no patient attrition and no final payer denials so far, suggesting strong early acceptance among insurers for this high‑cost gene therapy.

Manufacturing Speed and Reliability

Commercial manufacturing turnaround times are running about 23–24 days, with observed ranges of 23–26 days from biopsy to product readiness. Every valid biopsy has produced treatment sheets, most with double‑digit sheet counts, and the company has yet to report a harvest failure, an important proof point for scalability and margin visibility.

Pipeline Expansion with PSMA SIR‑T (ABO‑701)

Abeona broadened its portfolio by in‑licensing a PSMA‑directed SIR‑T oncology asset, ABO‑701, paying $7 million upfront plus about $1 million in milestones through Phase I. A pre‑IND meeting is set for early June 2026, with an IND filing and first‑in‑human study targeted for the second half of 2027 and deal options later ranging from co‑development to an out‑license structure.

R&D Mix Shift and Capital Discipline

R&D expense in Q1 2026 totaled $9.6 million, modestly lower than $9.9 million a year earlier despite the $7 million PSMA license payment. Excluding that transaction, R&D declined as certain manufacturing costs shifted into inventory post‑approval, and management guided to only minimal additional PSMA spending this year in the low single‑digit millions.

Operational Momentum and Physician Engagement

Commercial teams are seeing a growing funnel, with a near‑term pool of more than 100 potential patients identified across centers and community practices. Abeona is actively engaged with 45 referring physicians, and early feedback from QTCs suggests process improvements across the treatment pathway that could support a steadier flow of cases.

Gross‑to‑Net Dynamics and Revenue Quality

First‑quarter revenue was entirely from commercial payers, a mix that supports favorable gross‑to‑net compared with earlier Medicaid‑heavy activity. Looking ahead, management expects gross‑to‑net adjustments to settle in the mid‑ to upper‑teens percentage range as volume scales and the payer mix normalizes.

Wider Net Loss Amid Commercial Investment

Net loss widened to $17.1 million, or $0.30 per share, in Q1 2026 compared with $12.0 million, or $0.24 per share, in the prior‑year period. The increase of about 42% reflects heavier commercial spending behind the ZEVASKYN launch and the one‑time $7 million PSMA upfront payment, both framed as deliberate investments in growth.

Rising Operating Expenses and SG&A Growth

Selling, general and administrative expenses climbed to $19.5 million in the quarter, up $9.7 million year over year as Abeona built out its commercial infrastructure. Key drivers included $5.4 million in personnel and stock‑based compensation and $1.9 million tied to engineering runs supporting commercialization readiness.

Cash Position and Burn Profile

The company ended Q1 with $168.3 million in cash, cash equivalents and short‑term investments, down from $191.4 million at the end of 2025. The $23.1 million decrease underscores the ongoing cash burn required to scale a novel gene therapy business, even as management points to tightly managed R&D outlays.

Insurance Approvals and Medicaid Friction

Despite strong coverage statistics, Abeona noted that high‑priced gene therapies still face lengthy insurance approval processes, particularly for out‑of‑state Medicaid. These administrative hurdles introduce timing variability for when patients can be treated, though the company said it has not seen final denials so far.

Variable Onboarding and Biopsy Lead Times

Time from QTC activation to first patient biopsy remains unpredictable, with examples ranging from roughly two months to as long as six to seven months. Management estimates an average of four to five months for a new center to move from activation to first biopsy, which clouds short‑term revenue visibility even as long‑term capacity builds.

Rising Cost of Sales with Scaling

Cost of sales increased to $2.7 million in Q1 2026 compared with $1.0 million in Q4 2025 as treatment volumes ramped from one to three patients. Management framed the higher costs as a natural consequence of early scaling and as a base from which manufacturing efficiencies and volume leverage could later improve margins.

Operational Complexity of QTC Activation

Bringing each Qualified Treatment Center online requires multidisciplinary team readiness, senior management support, legal and contracting work and clinical and quality onboarding. This heavy lift means that it can take several months to more than a year for a center to become fully treatment‑ready, limiting how quickly Abeona can broaden its geographic reach.

Forward‑Looking Guidance and Launch Trajectory

Management’s outlook centers on a carefully paced launch and restrained pipeline spending, with one patient treated so far this quarter, one more in manufacturing and six additional biopsies anticipated, several potentially converting to Q2 revenue. The company expects gross‑to‑net to normalize in the mid‑ to upper‑teens, minimal PSMA R&D outlay this year, progress toward an IND in 2027 and hinted that monthly profitability might be reachable as early as June if biopsy and treatment cadence align.

Abeona’s call painted the picture of an emerging commercial gene therapy story balancing rapid top‑line growth against the realities of high fixed costs and operational complexity. For investors, the key watch items will be patient throughput per center, the pace of QTC activations, cash burn versus revenue growth and early signals from the PSMA oncology program as the company works to turn early promise into sustainable profitability.